Insiders · BBIO

Neil Kumar

Chief Executive Officer, Director at BridgeBio Pharma, Inc. (BBIO)

Neil Kumar has filed 89 insider reports with the SEC since February 2021, as chief Executive Officer and director at BridgeBio Pharma, Inc. (BBIO), director at BridgeBio Oncology Therapeutics, Inc. (BBOT) and director at Maze Therapeutics, Inc. (MAZE). In the last 12 months Neil Kumar sold $52.2M of stock on the open market. On November 18, 2026 Neil Kumar filed a Form 144 notice and plans to sell 34,980 BBIO shares (~$2.69M). The latest filing, on November 19, 2026, reports shares withheld for taxes or exercise price and exercise or conversion of a derivative at BridgeBio Pharma, Inc. (BBIO).

Planned sale (Form 144)

  • Neil Kumar plans to sell 34,980 BBIO shares (~$2.69M), around Nov 18, 2026. Notice filed Nov 18, 2026.

A Form 144 is a notice of a proposed sale, not a trade. The sale itself shows up in a later Form 4.

Filings
89
Companies
3
Bought on market
None
Sold on market
$120M

Companies where Neil Kumar is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
BridgeBio Pharma, Inc. logo
BBIO
BridgeBio Pharma, Inc.
Chief Executive Officer, Director278,307$120M$78.01Nov 19, 2026
BridgeBio Oncology Therapeutics, Inc. logo
BBOT
BridgeBio Oncology Therapeutics, Inc.
Directorsince August 2025$1.805Jun 18, 2026
Maze Therapeutics, Inc. logo
MAZE
Maze Therapeutics, Inc.
Directorsince March 2026$31.20Mar 31, 2026

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Also sits on boards with

Officers and directors who share two or more companies with Neil Kumar.

Compare Neil Kumar with

Other insiders at the same companies

Questions about Neil Kumar

What is Neil Kumar's role at BridgeBio Pharma, Inc.?
Neil Kumar reports to the SEC as chief Executive Officer and director at BridgeBio Pharma, Inc. (BBIO), according to the latest filing on November 19, 2026. Neil Kumar has also filed as director at BridgeBio Oncology Therapeutics, Inc. (BBOT) and director at Maze Therapeutics, Inc. (MAZE).
How many shares does Neil Kumar own?
After the latest filing that states it, Neil Kumar directly owned 278,307 shares of BridgeBio Pharma, Inc. (BBIO). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Neil Kumar bought or sold stock recently?
The most recent open-market sale was on September 17, 2026: sold 10,000 shares of BridgeBio Pharma, Inc. (BBIO) for $691K at an average of $69.08.
How do I get alerts when Neil Kumar files?
Follow Neil Kumar on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale. Neil Kumar filed 3 times in the last 90 days.

From SEC Forms 3, 4, 5 and 144 filed by Neil Kumar (SEC CIK 0001742485). Totals count each trade once, skipping amendments whose original is on file, from Feb 12, 2021 on. View on SEC EDGAR